Summary
The paper discusses the potential of bipolar cell targeted optogenetic gene therapies to restore high-level vision in human patients with end-stage retinal degenerations.
Categories
Eye health: The paper discusses the use of optogenetic gene therapies to restore vision in patients with retinal degenerations.
Phototherapy: The paper discusses the use of light-sensitive proteins to restore vision, a form of phototherapy.
Aging: The paper discusses the restoration of vision in patients with end-stage retinal degenerations, a condition that often occurs with aging.
Author(s)
J Kralik, M van Wyk, N Stocker, S Kleinlogel
Publication Year
2022
Number of Citations
16
Related Publications
Eye health
- Phototransduction by retinal ganglion cells that set the circadian clock
- Color appearance models
- Diminished pupillary light reflex at high irradiances in melanopsin-knockout mice
- Strange vision: ganglion cells as circadian photoreceptors
- Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa
Phototherapy
- Phototransduction by retinal ganglion cells that set the circadian clock
- Strange vision: ganglion cells as circadian photoreceptors
- Function of human pluripotent stem cell-derived photoreceptor progenitors in blind mice
- Lux vs. wavelength in light treatment of Seasonal Affective Disorder
- Short‐wavelength enrichment of polychromatic light enhances human melatonin suppression potency
Aging
- Light therapy and Alzheimer's disease and related dementia: past, present, and future
- Function of human pluripotent stem cell-derived photoreceptor progenitors in blind mice
- Melanopsin-expressing intrinsically photosensitive retinal ganglion cells in retinal disease
- Neuroprotective strategies for retinal ganglion cell degeneration: current status and challenges ahead
- Combinatorial effects of alpha-and gamma-protocadherins on neuronal survival and dendritic self-avoidance